Compare GSK plc (GSK) vs NIO Inc. (NIO) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

NIO trades at $5.02, up 1.83% today, showing resilience amid bearish technical signals. The company reported strong Q2 2026 vehicle deliveries with 62.9% year-over-year growth, while financials reveal ongoing losses with a net income margin of -9.09% for 2025. Analyst sentiment remains positive with 54% buy ratings, including a recent Goldman Sachs upgrade to Buy with a $7 target.

NIO presents a high-risk, high-reward opportunity with strong delivery growth offset by persistent profitability challenges. The path to profitability remains the key investment thesis, with recent margin improvements and premium vehicle mix providing potential upside. Significant risks include intense EV competition, cash burn, and regulatory uncertainties in the Chinese market.